We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect BeOne Medicines Ltd. - Sponsored ADR (ONC - Free Report) to post quarterly earnings of $3.51 per share in its upcoming report, which indicates a year-over-year increase of 222%. Revenues are expected to be $1.76 billion, up 24.4% from the year-ago quarter.
The current level reflects an upward revision of 0.5% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific BeOne Medicines Ltd. - Sponsored ADR metrics that are commonly monitored and projected by Wall Street analysts.
It is projected by analysts that the 'Revenues- Product revenue, net' will reach $1.74 billion. The estimate suggests a change of +24.5% year over year.
The combined assessment of analysts suggests that 'Revenues- Product Revenue- Other' will likely reach $30.22 million. The estimate indicates a change of +50.3% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Product Revenue- BRUKINSA(Zanubrutinib)' reaching $1.31 billion. The estimate indicates a change of +25.6% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenues- Product Revenue- XGEVA' should arrive at $89.05 million. The estimate suggests a change of +5.7% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Product Revenue- BLINCYTO' of $38.70 million. The estimate suggests a change of +27% year over year.
The average prediction of analysts places 'Revenues- Product Revenue- KYPROLIS' at $16.08 million. The estimate indicates a change of -12.5% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Product Revenue- TEVIMBRA' will reach $231.55 million. The estimate indicates a change of +21.5% from the prior-year quarter.
Analysts forecast 'Revenues- Product Revenue- POBEVCY' to reach $9.97 million. The estimate indicates a year-over-year change of -5%.
BeOne Medicines Ltd. - Sponsored ADR shares have witnessed a change of -0.1% in the past month, in contrast to the Zacks S&P 500 composite's -2.3% move. With a Zacks Rank #1 (Strong Buy), ONC is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key Metrics
Wall Street analysts expect BeOne Medicines Ltd. - Sponsored ADR (ONC - Free Report) to post quarterly earnings of $3.51 per share in its upcoming report, which indicates a year-over-year increase of 222%. Revenues are expected to be $1.76 billion, up 24.4% from the year-ago quarter.
The current level reflects an upward revision of 0.5% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific BeOne Medicines Ltd. - Sponsored ADR metrics that are commonly monitored and projected by Wall Street analysts.
It is projected by analysts that the 'Revenues- Product revenue, net' will reach $1.74 billion. The estimate suggests a change of +24.5% year over year.
The combined assessment of analysts suggests that 'Revenues- Product Revenue- Other' will likely reach $30.22 million. The estimate indicates a change of +50.3% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Product Revenue- BRUKINSA(Zanubrutinib)' reaching $1.31 billion. The estimate indicates a change of +25.6% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenues- Product Revenue- XGEVA' should arrive at $89.05 million. The estimate suggests a change of +5.7% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Product Revenue- BLINCYTO' of $38.70 million. The estimate suggests a change of +27% year over year.
The average prediction of analysts places 'Revenues- Product Revenue- KYPROLIS' at $16.08 million. The estimate indicates a change of -12.5% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Product Revenue- TEVIMBRA' will reach $231.55 million. The estimate indicates a change of +21.5% from the prior-year quarter.
Analysts forecast 'Revenues- Product Revenue- POBEVCY' to reach $9.97 million. The estimate indicates a year-over-year change of -5%.
View all Key Company Metrics for BeOne Medicines Ltd. - Sponsored ADR here>>>BeOne Medicines Ltd. - Sponsored ADR shares have witnessed a change of -0.1% in the past month, in contrast to the Zacks S&P 500 composite's -2.3% move. With a Zacks Rank #1 (Strong Buy), ONC is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .